Hi, I'm Mahi Muqit. I'm a consultant vitreoretinal surgeon at Moorefields Eye Hospital and a UCL associate professor. I'm pleased to report the three-year results of the PRIMAVERA trial, the final readout at Euretina 2026. It's very timely. After our New England Journal of Medicine publication last year where we demonstrated for the first time meaningful clinical improvement of restoration of vision for patients with geographic atrophy and dry age-related macular degeneration. We now have the three-year data, which is important for professionals and patients to hear. And we're pleased to inform that PRIMA, the neurostimulation implants, provides durable, sustained visual functional benefits for patients up to three years. Almost 80% of patients who remain on the trial are demonstrating significant improvements in LogMAR visual acuity. And with magnification, they can see up to three or four lines of ETDRS charts. So it's extremely important to understand how this device provides lasting improvement.

In fact, we're actually now seeing that patients are able to improve their activities of daily life with rehabilitation and patients are now performing outdoors and indoors many tasks outside the clinical trial, which is extremely important for quality of life for our patients.